Show simple item record

dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorCappuzzo, F
dc.date.accessioned2016-11-01T13:58:30Z
dc.date.available2016-11-01T13:58:30Z
dc.date.issued2016-09
dc.identifier.citationCrizotinib: from discovery to accelerated development to front-line treatment. 2016, 27(Suppl 3):iii35-iii41 Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid27573754
dc.identifier.doi10.1093/annonc/mdw304
dc.identifier.urihttp://hdl.handle.net/10541/619990
dc.description.abstractNon-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC. Crizotinib demonstrated rapid and durable responses in advanced ALK-positive NSCLC patients in phase I and II studies, leading to accelerated FDA approval. Subsequent evaluation in phase III studies showed that crizotinib improved progression-free survival compared with platinum-based doublet chemotherapy in previously untreated patients and compared with pemetrexed or docetaxel in previously treated patients. Crizotinib was shown to have an acceptable safety profile and also to improve quality of life and symptom scores. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK-positive NSCLC.
dc.languageENG
dc.language.isoenen
dc.relation.urlhttp://annonc.oxfordjournals.org/content/27/suppl_3/iii35.full.pdf+htmlen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.titleCrizotinib: from discovery to accelerated development to front-line treatment.en
dc.typeArticleen
dc.contributor.departmentChristie NHS Foundation Trust, Institute of Cancer Sciences, University of Manchester, Manchesteren
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-04-03T11:32:45Z
html.description.abstractNon-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC. Crizotinib demonstrated rapid and durable responses in advanced ALK-positive NSCLC patients in phase I and II studies, leading to accelerated FDA approval. Subsequent evaluation in phase III studies showed that crizotinib improved progression-free survival compared with platinum-based doublet chemotherapy in previously untreated patients and compared with pemetrexed or docetaxel in previously treated patients. Crizotinib was shown to have an acceptable safety profile and also to improve quality of life and symptom scores. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK-positive NSCLC.


Files in this item

Thumbnail
Name:
Crizotinib- from discovery to ...
Size:
202.0Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record